Combination therapy using 1-aminocyclohexane derivatives and...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/13 (2006.01) A61K 31/16 (2006.01) A61K 31/27 (2006.01) A61K 31/435 (2006.01) A61K 31/445 (2006.01) A61K 31/473 (2006.01) A61K 31/55 (2006.01) A61P 25/00 (2006.01)

Patent

CA 2502432

A drug combination therapy useful in the treatment of dementia associated with disorders of the central nervous system, e.g. to delay the onset or progression of Alzheimer~s disease, cerebrovascular disease or Down~s syndrome, comprises a combination of a 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor such as galantamine, tacrine, donepezil or rivastigmine.

Cette invention a trait à une thérapie reposant sur une combinaison de médicaments, des plus utiles pour traiter la démence liée à des troubles du système nerveux central, notamment, pour retarder, l'apparition ou l'évolution de la maladie d'Alzheimer, de maladies cérébro-vasculaires ou du syndrome de Down. Cette thérapie fait appel à une combinaison d'un dérivé de 1-aminocyclohexane, mémantine ou néramexane et d'un inhibiteur de l'acétylcholinestérase tel que galantamine, tacrine, donepezil ou rivastigmine.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Combination therapy using 1-aminocyclohexane derivatives and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy using 1-aminocyclohexane derivatives and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy using 1-aminocyclohexane derivatives and... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1755613

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.